Biotechnology - Biotechnology, Dainippon Sumitomo Pharma

Filter

Popular Filters

FDA approves Northera for neurogenic orthostatic hypotension

FDA approves Northera for neurogenic orthostatic hypotension

19-02-2014

Shares of US biotech firm Chelsea Therapeutics soared 38% to $6.75 in after-hours trading yesterday,…

BiotechnologyChelsea TherapeuticsDainippon Sumitomo PharmaNorth AmericaNortheraRare diseasesRegulationUSA

Dainippon Sumitomo establishes regenerative and cellular medicine office

12-08-2013

Japanese drug major Dainippon Sumitomo Pharma (TYO: 4506) says that it has set up the Regenerative &…

Asia-PacificBiotechnologyDainippon Sumitomo PharmaPharmaceuticalProductionResearch

US FDA backs news indications for Latuda; grants Priority Review for Perjeta

02-07-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

BiotechnologyDainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaOncologyPerjetaPharmaceuticalRegulationRocheSunovion

Dainippon Sumitomo to set up DSP Cancer Institute

21-08-2012

Japanese drug major Dainippon Sumitomo Pharma (TYO: 4506) says it plans to establish a new organization…

BiotechnologyDainippon Sumitomo PharmaManagementOncologyPharmaceuticalResearch

Company Spotlight

ImmunoGen

ImmunoGen

Back to top